R&G PharmaStudies Co. Ltd. A (SHE:301333) — Market Cap & Net Worth
Market Cap & Net Worth: R&G PharmaStudies Co. Ltd. A (301333)
R&G PharmaStudies Co. Ltd. A (SHE:301333) has a market capitalization of $898.43 Million (CN¥6.14 Billion) as of August 15, 2026. Listed on the SHE stock exchange, this China-based company holds position #9399 globally and #2370 in its home market, demonstrating a 23.92% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying R&G PharmaStudies Co. Ltd. A's stock price CN¥63.57 by its total outstanding shares 96581256 (96.58 Million). See R&G PharmaStudies Co. Ltd. A (301333) net asset quality to understand what proportion of total assets are financed by equity.
R&G PharmaStudies Co. Ltd. A Market Cap History: 2022 to 2026
R&G PharmaStudies Co. Ltd. A's market capitalization history from 2022 to 2026. Data shows growth from $719.71 Million to $898.43 Million (3.35% CAGR). Also see R&G PharmaStudies Co. Ltd. A balance sheet assets for a full breakdown of the balance sheet.
R&G PharmaStudies Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how R&G PharmaStudies Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of R&G PharmaStudies Co. Ltd. A for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.99x
R&G PharmaStudies Co. Ltd. A's market cap is 0.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
6.15x
R&G PharmaStudies Co. Ltd. A's market cap is 6.15 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $719.71 Million | $637.52 Million | $113.45 Million | 1.13x | 6.34x |
| 2023 | $906.09 Million | $721.37 Million | $162.53 Million | 1.26x | 5.57x |
| 2024 | $706.50 Million | $744.00 Million | $140.22 Million | 0.95x | 5.04x |
| 2025 | $841.61 Million | $851.01 Million | $136.90 Million | 0.99x | 6.15x |
Competitor Companies of 301333 by Market Capitalization
Companies near R&G PharmaStudies Co. Ltd. A in the global market cap rankings as of August 15, 2026. Also see R&G PharmaStudies Co. Ltd. A cash flow conversion for how efficiently the company converts equity into cash flow.
Key companies related to R&G PharmaStudies Co. Ltd. A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #224 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #429 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #547 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- Samsung Biologics Co Ltd (KO:207940): Ranked #553 globally with a market cap of $49.06 Billion USD ( ₩72.40 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #224 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $516.44 |
| #429 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $805.97 |
| #547 | Argen-X | BR:ARGX | $49.55 Billion | €754.40 |
| #553 | Samsung Biologics Co Ltd | KO:207940 | $49.06 Billion | ₩1564000.00 |
R&G PharmaStudies Co. Ltd. A Historical Marketcap From 2022 to 2026
Between 2022 and today, R&G PharmaStudies Co. Ltd. A's market cap moved from $719.71 Million to $ 898.43 Million, with a yearly change of 3.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥898.43 Million | +6.75% |
| 2025 | CN¥841.61 Million | +19.12% |
| 2024 | CN¥706.50 Million | -22.03% |
| 2023 | CN¥906.09 Million | +25.90% |
| 2022 | CN¥719.71 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 14th, 2026 the market cap of R&G PharmaStudies Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $898.43 Million USD |
| MoneyControl | $898.43 Million USD |
| MarketWatch | $898.43 Million USD |
| marketcap.company | $898.43 Million USD |
| Reuters | $898.43 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About R&G PharmaStudies Co. Ltd. A
R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It offers drug clinical research and development integrated services. The company's services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology se… Read more